Who is sponsoring NCT06059859?

NCT06059859 is sponsored by European Institute of Oncology.

What drugs are being tested in NCT06059859?

Interventions in NCT06059859: Augmented reality robot-assited radical prostatectomy, Mixed reality intraoperative frozen section analysis, Robot-assited radical prostatectomy.

What condition does NCT06059859 study?

NCT06059859 studies Prostatic Neoplasm.

Is NCT06059859 still recruiting?

NCT06059859 is currently recruiting now. Last updated 12 August 2025.

Last reviewed 2025-08-12 · How we verify

NCT06059859

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Augmented Reality During Robot-assisted Radical Prostatectomy

Recruiting now NA Last updated 12 August 2025

What this trial tests

NA trial testing Augmented reality robot-assited radical prostatectomy in Prostatic Neoplasm in 318 participants. Currently enrolling.

Timeline

1 January 2022

Primary endpoint
1 January 2026

1 January 2026

Quick facts

Lead sponsor	European Institute of Oncology
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	318
Start date	1 January 2022
Primary completion	1 January 2026
Estimated completion	1 January 2026
Sites	1 location across Italy

Drugs / interventions tested

Augmented reality robot-assited radical prostatectomy
Mixed reality intraoperative frozen section analysis
Robot-assited radical prostatectomy

Conditions studied

Prostatic Neoplasm — all drugs for Prostatic Neoplasm →

Sponsor

European Institute of Oncology

Who can join

Adults 18 to 70, male only, with Prostatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Accurate preservation of neuro-vascular bundles is crucial in guaranteeing erectile function recovery after robot assisted radical prostatectomy (RARP). However, the nerve sparing approach is associated with higher rates of positive surgical margins (PSM) at final pathology. Augmented reality (AR) RARP was previously associated with a 10-15% reduction in the rates of PSMs in two retrospective series. However, prospective studies are needed to demonstrate clinical utility and to validate these technologies. The hypotheses of this study are that: 1) AR RARP reduces the rates of PSMs, if compared to standard approach; 2) AR RARP can guarantee a more accurate preservation of neurovascular bundles and, in consequence, a greater recovery of erectile function; 3) the lower rates of PSMs will translate in greater oncological control of the disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Phase 3 Prospective Randomized Trial to Evaluate the Impact of Augmented Reality During Robot-assisted Radical Prostatectomy on the Rates of Postoperative Surgical Margins: A Clinical Trial Protocol.
Musi G, Mistretta FA, de Cobelli O, Bellin A, et al · · 2024 · cited 4× · PMID 38333626 · DOI 10.1016/j.euros.2024.01.006

Verify or expand the search:

Other recruiting trials for Prostatic Neoplasm

Currently open trials in the same condition.

NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
NCT05968144 — Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness · Phase 1, PHASE2 · active not recruiting
NCT05849298 — A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC · Phase 2 · active not recruiting
NCT06292897 — Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression · recruiting
NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting

Other European Institute of Oncology trials

Trials by the same sponsor.

NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06059859 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
Last refreshed: 12 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06059859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing